

THE HEART OF WOMEN'S HEALTH

Women, compared with men, are **less likely to receive GDMT** or **appropriate intensification of therapy**

Lower rates of **ACEI/ARBs** post STEMI

Fewer achieve door-to-balloon time **≤90 minutes**

Lower rate of **diagnostic testing/specialty care**

Fewer restoration procedures e.g., revascularization



Lower rate for OAC for new AFib
48% vs. **53%**

Lower statin prescription rate
67% vs. **78%**

Lower GDMT-based **statin intensity**
36.7% vs. **45.2%**

Higher death rate from high BP
52.2% vs. **47.8%**

The Impact of Gaps in Care

THE IMPACT OF GAPS IN CARE

CVD

#1 cause of death in women, responsible for **1 of 4 deaths**[6]

Greater morbidity and mortality post stroke and MI[7-8]

Toll of Ischemic Heart Disease in Women vs. Men[9]

MI
~1.5x higher 1-year mortality

CABG
~2x higher morbidity/mortality

HF
~1.5x higher incidence

Angina
~2x higher morbidity/mortality

Sex-Based Differences

SEX-BASED DIFFERENCES

Myth: Higher Bleeding Risk in Women
Fact: Similar to Men

Significantly **lower risk** of **intracranial hemorrhage**[10]

DOACs vs. Warfarin	All-cause mortality
HR: 0.16	HR: 0.55

HFpEF, Nonobstructive CAD Higher in Women

2x as likely to develop **HFpEF**; experience greater symptom burden[11]

More likely to have **nonobstructive CAD**

Inconsistent MI symptoms leading to **delayed diagnosis & treatment**

Response to Medical Management

Post hoc analysis of major clinical trials:

TOPCAT[12]**:**
Secondary outcome of all-cause mortality:

15.8%	Spironolactone therapy	25.2%
22.3%	Placebo	24.3%

PARAGON-HF[13]**:**

Sacubitril/Valsartan treatment → **Greater response by women**

Call to Action

Addressing the disparities in delivery of care and cardiovascular outcomes for women requires a renewed commitment to recognizing the issue and prescribing GDMT and other evidence-based treatment.

Abbreviations:

AFib: Atrial fibrillation | CABG: Coronary artery bypass grafting | CAD: Coronary artery disease | CHD: Coronary heart disease | DOAC: Direct oral anticoagulant | HF: Heart Failure | HFpEF: Heart failure with preserved ejection fraction | HTN: Hypertension | ICH: Intracerebral hemorrhage | IHD: Ischemic heart disease | MI: Myocardial infarction

References:

1. Turakhia MP. Presented at: HRS2019. May 10, 2019. San Francisco, CA. | 2. Nanna MG, et al. Circ Cardiovasc Qual Outcomes 2019 Aug;12(8):e005562. | 3. Benjamin EJ, et al. Circulation 2019 Mar;139(10):e56-e528. | 4.Bozkurt B, et al. Methodist Debakey Cardiovasc J 2017;13(4):216–223. | 5. Bangalore S, et al. Am J Med 2012;125(10):1000-1009. | 6. Virani SS, et al. Circulation 2020;141:e139–e596. | 7. Woodward M. Int J Environ Res Public Health 2019 Apr;16(7):1165. | 8. Graham G. Clin Med Insights Cardiol 2016;10:1–10. | 9. Sanghavi M and Gulati M. Curr Atheroscler Rep 2015 Jun;17(6):511. | 10. Law SW, et al. J Am Coll Cardiol 2018 Jul;72(3):271-282. | 11. Garcia M, et al. Circ Res 2016;118(8):1273-93. | 12. Pitt B, et al. N Engl J Med 2014;370(15):1383-92. | 13. Solomon SD, et al. N Engl J Med 2019;381:1609-1620.

Educational Grant Support Provided by:

Amarin, AstraZeneca, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharmaceuticals Corporation